Last update 16 Jul 2024

Encorafenib

Overview

Basic Info

Drug Type
Small molecule drug
Synonyms
Encorafenib (JAN/USAN/INN), LGX-818, LGX818
+ [6]
Target
Mechanism
BRAF inhibitors(Serine/threonine-protein kinase B-raf inhibitors)
Originator Organization
Inactive Organization-
Drug Highest PhaseApproved
First Approval Date
RegulationOrphan Drug (US), Priority Review (AU)
Login to view First Approval Timeline

Structure

Molecular FormulaC22H27ClFN7O4S
InChIKeyCMJCXYNUCSMDBY-ZDUSSCGKSA-N
CAS Registry1269440-17-6

External Link

R&D Status

Approved
10 top approved records.
Login
to view more data
IndicationCountry/LocationOrganizationDate
BRAF mutated anaplastic thyroid cancer
JP
17 May 2024
Thyroid Cancer with BRAF mutation
JP
17 May 2024
BRAF V600E mutant Non-small Cell Lung Cancer
US
11 Oct 2023
BRAF V600 mutant Colorectal Cancer
KR
19 Aug 2021
BRAF mutation positive Melanoma
JP
27 Nov 2020
BRAF Mutation colorectal cancers
JP
08 Jan 2019
BRAF V600E Mutation-Positive Melanoma
AU
03 Jan 2019
BRAF V600K Mutation-Positive Melanoma
AU
03 Jan 2019
BRAF V600E mutant Colorectal Cancer
EU
19 Sep 2018
BRAF V600E mutant Colorectal Cancer
IS
19 Sep 2018
BRAF V600E mutant Colorectal Cancer
LI
19 Sep 2018
BRAF V600E mutant Colorectal Cancer
NO
19 Sep 2018
BRAF V600 mutation-positive Melanoma
US
27 Jun 2018
Developing
10 top R&D records.
Login
to view more data
IndicationHighest PhaseCountry/LocationOrganizationDate
Metastatic melanomaPhase 3
US
15 Jan 2021
Metastatic melanomaPhase 3
AR
15 Jan 2021
Metastatic melanomaPhase 3
AT
15 Jan 2021
Metastatic melanomaPhase 3
BE
15 Jan 2021
Metastatic melanomaPhase 3
BR
15 Jan 2021
Metastatic melanomaPhase 3
BG
15 Jan 2021
Metastatic melanomaPhase 3
CA
15 Jan 2021
Metastatic melanomaPhase 3
CZ
15 Jan 2021
Metastatic melanomaPhase 3
FI
15 Jan 2021
Metastatic melanomaPhase 3
FR
15 Jan 2021
Login to view more data

Clinical Result

Indication
Phase
Evaluation
View All Results
Study
Phase
PopulationAnalyzed EnrollmentGroupResultsEvaluationPublication Date
Phase 1
3
ptfbvvmfrt(fvjbzmuxfu) = ogewoqffbx pyxxnbpeol (tpdqxzceim, mbkhndjfkk - fucosqonti)
-
24 Jun 2024
Phase 2
BRAF V600E mutant Colorectal Cancer
Second line | Third line
BRAF V600E mutation
97
doeprrgnjp(gztmrxeqsx) = lutuzasyte eccugprqyj (qtdcznhhio )
Positive
02 Jun 2024
Irinotecan + Cetuximab or FOLFIRI + Cetuximab
doeprrgnjp(gztmrxeqsx) = bedbnzqkvv eccugprqyj (qtdcznhhio )
Phase 2
135
nzxftpchzp(kecicpuwwe): HR = 0.87 (90% CI, 0.67 - 1.12), P-Value = 0.36
Negative
02 Jun 2024
Not Applicable
Metastatic melanoma
First line
Lactate dehydrogenase levels
208
Encorafenib/binimetinib
eejjrgkqmk(fbdmwsvwyw) = dulyjuslhs uoifjtnymu (imepzqejrh )
Positive
24 May 2024
Not Applicable
300
vmntqahzeq(syjlgovwog) = Treatment emergent adverse events (TEAE) were reported in 73% of pts (grade 3/4: 38%). Main TEAE (≥10%, all grades) were: rash (12%) and nausea (11%) kwryuxeihq (jvozwhjyvk )
Positive
24 May 2024
Chemotherapy plus cetuximab
Phase 2
5
Research Bloods+Encorafenib+Binimetinib
(Treatment Cohort 1 AA & GBM)
gytpjxgfrw(pqeuoxkcqb) = bnjoxeiqvo ybizyalgaz (qcorssvrau, kbyqlmzjrm - xdjbpfetlx)
-
06 Mar 2024
Research Bloods+Encorafenib+Binimetinib
(Treatment Cohort 2 Anaplastic PXAs)
gytpjxgfrw(pqeuoxkcqb) = ogtezvtxag ybizyalgaz (qcorssvrau, serrwyxpdy - bbgaytsjhs)
Phase 2
6
rmzhiyqfnq(ucbplgcbzz) = taltocicpu hkplwlqgaq (jlpoftfvfz, idudrjbjwx - ngmykfllqq)
-
23 Jan 2024
Not Applicable
Colorectal Cancer
BRAF V600E mutation
125
Encorafenib + Cetuximab
zxlihonqas(hjuncnauyl) = uitjhkueay lrzyexxsub (ktzsnsulnr )
-
18 Jan 2024
Encorafenib + Panitumumab
zxlihonqas(hjuncnauyl) = azretxhmuj lrzyexxsub (ktzsnsulnr )
Phase 3
577
zuqxulenfg(jeatwmhwlv) = Grade 3/4 TEAEs (≥5% with enco + bini) were γ-glutamyltransferase increased, blood CPK increased, hypertension, ALT increased, and anemia stwfhkvxth (wvzlusjtlq )
Positive
02 Dec 2023
Phase 2
98
(Treatment-Naive)
smkdikvevt(jtuntkopwf) = athxrdvsbb jgffceihlu (rtkxqakzhx, pgmcttbqcy - gmqrookvbv)
-
30 Oct 2023
(Previously Treated)
smkdikvevt(jtuntkopwf) = exmygjdlbv jgffceihlu (rtkxqakzhx, bfrtwdmigx - clwzqiyols)
Login to view more data

Translational Medicine

Boost your research with our translational medicine data.
Boost your research with our translational medicine data.

Deal

Boost your decision using our deal data.
Boost your decision using our deal data.

Core Patent

Boost your research with our Core Patent data.
Boost your research with our Core Patent data.

Clinical Trial

Identify the latest clinical trials across global registries.
Identify the latest clinical trials across global registries.

Approval

Accelerate your research with the latest regulatory approval information.
Accelerate your research with the latest regulatory approval information.

Regulation

Understand key drug designations in just a few clicks with Synapse.
Understand key drug designations in just a few clicks with Synapse.
Chat with Hiro
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Leverages most recent intelligence information, enabling fullest potential.
Bio
Bio Sequences Search & Analysis
Sign up for free
Chemical
Chemical Structures Search & Analysis
Sign up for free